Director Blake Borgeson filed a Form 144 notice on November 3, 2026, disclosing a proposed sale of 40,000 Class A shares of Recursion Pharmaceuticals, Inc. through Fidelity Brokerage Services LLC on NASDAQ:RXRX.

Key Highlights

  • Proposed sale: 40,000 Class A shares with an aggregate market value of $155,200.00, according to the filing.
  • Acquisition origin: The shares were acquired on September 19, 2017, as Founders Shares from the issuer, with compensation listed as the nature of payment.
  • Approximate sale date: November 3, 2026, to be executed through Fidelity Brokerage Services LLC on NASDAQ.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of August 31, 2025.
  • Shares outstanding: 622,759,259 Class A shares were reported outstanding at the time of the filing.
  • Prior sales in past 3 months: Borgeson sold a combined 110,000 Class A shares across three separate transactions between August and October 2026, generating gross proceeds of $439,700.00 in total.

Blake Borgeson's Proposed Class A Share Sale at Recursion Pharmaceuticals

According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 3, 2026, Blake Borgeson, a director of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), has provided notice of a proposed sale of 40,000 Class A shares. The filing lists the aggregate market value of those shares at $155,200.00. The shares are to be sold through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, on NASDAQ.

The filing discloses that the 40,000 shares slated for sale were originally acquired on September 19, 2017, as Founders Shares from the issuer, with compensation noted as the nature of payment. The filing also indicates that Borgeson is relying on a Rule 10b5-1 written trading plan with an adoption date of August 31, 2025. The issuer's address is listed as 41 S Rio Grande Street, Salt Lake City, Utah 84101.

In the three months preceding this notice, the filing reports that Blake C. Borgeson sold Class A shares on three occasions: 30,000 shares on August 4, 2026, for gross proceeds of $97,500.00; 30,000 shares on September 1, 2026, for gross proceeds of $100,200.00; and 50,000 shares on October 6, 2026, for gross proceeds of $242,000.00. The combined gross proceeds from those three prior transactions total $439,700.00, as reported in the filing.

What Was Disclosed

A Form 144 notice was filed on November 3, 2026, on behalf of Recursion Pharmaceuticals director Blake Borgeson, covering a proposed sale of 40,000 Class A shares valued at $155,200.00, acquired as Founders Shares in 2017, under a Rule 10b5-1 plan adopted August 31, 2025.